Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$216.00 USD

216.00
308,627

+0.93 (0.43%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (168 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

LabCorp (LH) Stock Moves -0.57%: What You Should Know

LabCorp (LH) closed the most recent trading day at $276.30, moving -0.57% from the previous trading session.

Analysts Estimate LabCorp (LH) to Report a Decline in Earnings: What to Look Out for

LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LabCorp (LH) Gains But Lags Market: What You Should Know

LabCorp (LH) closed at $271.14 in the latest trading session, marking a +1.5% move from the prior day.

LabCorp (LH) Gains As Market Dips: What You Should Know

LabCorp (LH) closed the most recent trading day at $264.88, moving +0.24% from the previous trading session.

LabCorp (LH) Dips More Than Broader Markets: What You Should Know

LabCorp (LH) closed the most recent trading day at $263.66, moving -1.99% from the previous trading session.

LabCorp (LH) Gains From Covance Arm Growth, Cost Pressure Ails

LabCorp's (LH) Covance Drug Development arm is benefiting from its collaborations with leading pharmaceutical and biotechnology companies.

LabCorp (LH) Outpaces Stock Market Gains: What You Should Know

LabCorp (LH) closed the most recent trading day at $273.96, moving +0.93% from the previous trading session.

LabCorp (LH) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, LabCorp (LH) closed at $271.44, marking a -0.09% move from the previous day.

Should Value Investors Consider LabCorp (LH) Stock Now?

Let's see if LabCorp (LH) stock is a good choice for value-oriented investors right now from multiple angles.

LabCorp (LH) Gains But Lags Market: What You Should Know

In the latest trading session, LabCorp (LH) closed at $274.33, marking a +0.11% move from the previous day.

LabCorp (LH) Stock Moves -0.27%: What You Should Know

LabCorp (LH) closed at $265.49 in the latest trading session, marking a -0.27% move from the prior day.

Here's Why You Should Hold on to LabCorp (LH) Stock For Now

Investors are optimistic about LabCorp's (LH) better-than-expected results and robust base business performance.

Walgreens (WBA) Expands Access to COVID-19 Test With LabCorp

Walgreens (WBA) will enable more communities to access reliable, convenient testing services as and when required with the addition of Pixel by LabCorp COVID-19 at-home collection kit.

Is John Hancock Multifactor Mid Cap ETF (JHMM) a Strong ETF Right Now?

Smart Beta ETF report for JHMM

Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?

Style Box ETF report for JHMM

LabCorp (LH) Expands Clinical Laboratory Services With New Pact

LabCorp's (LH) recent collaboration will enable it to administer Ascension's hospital-based laboratories in 10 states and purchase select assets of the health system's outreach laboratory business.

LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Down

LabCorp (LH) reports better-than-expected results for the fourth quarter, with solid contributions from the Drug Development business driving the top line.

LabCorp (LH) Q4 Earnings and Revenues Beat Estimates

LabCorp (LH) delivered earnings and revenue surprises of 14.75% and 2.95%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Device Stocks' Q4 Earnings on Feb 10: BIO, DXCM & LH

Medical device companies' Q4 results are likely to reflect an increase in COVID-19 testing demand. Let's see how BIO, DXCM, and LH are poised ahead of their earnings releases.

Why Earnings Season Could Be Great for Laboratory Corporation (LH)

Laboratory Corporation (LH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Cerner (CERN) to Report Q4 Earnings: What's in the Offing?

Cerner's (CERN) fourth-quarter results are likely to reflect gains from strategic deals.

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.

Doximity (DOCS) to Report Q3 Earnings: What's in the Cards?

Doximity's (DOCS) fiscal third-quarter results are likely to reflect growth in its telehealth platform and robust net revenue retention rate.

Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?

Robust uptake of dPCR products and a rebound in routine testing are likely to have contributed to Bio-Rad's (BIO) Q4 top line.

LabCorp (LH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.